-+ 0.00%
-+ 0.00%
-+ 0.00%
Cushman & Wakefield sees U.S. life sciences real estate market rebalancing as development slows
Share
Listen to the news
Cushman & Wakefield sees U.S. life sciences real estate market rebalancing as development slows
  • Cushman & Wakefield flagged a gradual rebalancing in U.S. life sciences real estate as new development slows, despite elevated vacancy.
  • Q2 2026 asking rents averaged $64.17 psf, down 2.2% QOQ, down 5.3% YOY; still 37% above traditional office.
  • Vacancy rose to 24.3% in Q2 2026 from 23.4% at end-2025; sublease vacancy eased to 3.4%.
  • Pipeline fell below 6 msf under construction, or 2% of inventory, versus 35 msf in 2023; 4.4 msf delivers through 2027, 69% preleased.
  • R&D sales volume reached $9.3 billion over four quarters through Q2 2026, up 4% YOY; life sciences VC funding topped $17.7 billion in H1 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cushman & Wakefield Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608311631BIZWIRE_USPR_____20260831_BW912875) on August 31, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending